Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 16/20 | 0.53 |
| ▸ | AKT1 | P31749 | 16/20 | 0.53 |
| ▸ | RPS6KA1 | Q15418 | 14/20 | 0.53 |
| ▸ | AKT2 | P31751 | 10/20 | 0.53 |
| ▸ | RPS6KA5 | O75582 | 9/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | PRKACA | P17612 | 2/20 | 0.53 |
| ▸ | MARK3 | P27448 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | PRKX | P51817 | 2/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487842 | 0.96 | ROCK1 (0.52) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL690257 | 0.91 | ROCK1 (0.54) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13461477 | 0.91 | ROCK1 (0.56) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL4687918 | 0.90 | AKT1 (0.52) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3488105 | 0.88 | SLC2A1 (0.47) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487648 | 0.88 | AKT1 (0.71) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487998 | 0.86 | SLC2A1 (0.47) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL4685637 | 0.86 | ROCK1 (0.53) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487791 | 0.86 | AKT1 (0.54) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3489138 | 0.83 | AKT1 (0.70) | ROCK1AKT1RPS6KA1AKT2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008063853-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | ROCK1 478/4885AKT1 5/4885RPS6KA1 127/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | ROCK1 478/4885AKT1 5/4885RPS6KA1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.